82 search results for: chronic inflammation
Immunological Drivers in CSU: Diverse Pathways to Mast Cell Activation
In this video from EADV 2025, Dr. Hawkes reviews the pathophysioogy of CSU with a focus on the role of type 2 inflammation
ADVENT at ERS-ISIAN 2025
Join experts Vibeke Backer, MD, DMSC, and Sietze Reitsma, MD, at an educational symposium involving a comprehensive exploration of the type 2 inflammation and its pivotal role in the pathogenesis and management of CRSwNP.
World Anosmia Awareness Day
Explore our educational resources about loss of smell and the role of type 2 inflammation in CRSwNP, featuring expert insights from Profs. Wytske Fokkens and Joaquim Mullol.
ADVENT in Orlando, 2025
Type 2 inflammation contributes to many dermatologic diseases, which may lead to potentially life-changing burdens and challenges to patients and caregivers. By uncovering the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP, we can move forward in our understanding of each disease. Join global experts for an educational symposium on March 8th that will uncover the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP and explore questions driving current research in each disease.
Emerging Therapeutics: Addressing the Gaps in CSU Patient Care
In this video from EADV 2025, Professor Metz shares exciting data from therapies recently approved or in late-stage development for CSU.
Broadening the Lens: Clinical and Immunological Insights That Inform CSU Management
Professors Metz, Netchiporouk, and Hawkes discuss the clinical features, pathophysiology, and therapeutic landscape of CSU, at EADV 2025.
ADVENT Forum 2025 Event Page
From the April 2025 ADVENT Forum in Lisbon, Portugal, this event page serves to spotlight curated soundbites from dermatology and immunology experts that connect the evolving science of type 2 inflammation to clinical application.
EADV 2025 Congress
ADVENT at EADV 2025: Join Sanofi and Regeneron for three educational symposia on AD, CSU, and BP.
CRSwNP at Center Stage: Impact of Biologics in Patients with Co-existing Type 2 Asthma
In this video soundbite from the EAACI 2025 symposium, Dr. Philippe Gevaert explains how biologic options for uncontrolled CRSwNP are increasing, and phase 3 studies of approved biologics show improved outcomes and decreased SCS use/surgery in patients with CRSwNP. Additionally, he explains how biologics targeting type 2 inflammatory pathophysiology potentially improve outcomes for eligible patients with co-existing CRSwNP and asthma.
ADVENT at IRS-ISIAN | The Importance of Understanding Smell Loss and Congestion in CRSwNP
Join Profs. Sachio Takeno and Joaquim Mullol for an educational symposium highlighting the multifaceted burden associated with loss of smell and congestion in patients with uncontrolled CRSwNP.
